Retroperitoneal Biopsy Guidelines

Indications and Approach

The European Society for Medical Oncology recommends core needle biopsy via a retroperitoneal approach as the standard procedure for diagnosing retroperitoneal masses, with minimal risk of complications (<2%) and negligible risk of needle tract seeding (<0.5%) 1, 2, 3
Biopsy is mandatory before proceeding with major surgical resection to definitively distinguish malignant from benign disease and to exclude lymphoma or germ cell tumors, which require completely different treatment approaches than sarcomas 4, 5

Comprehensive cross-sectional imaging (CT/MRI) must be obtained to assess tumor extent and plan the biopsy trajectory, as recommended by the European Society for Medical Oncology 3, 6
The biopsy pathway must be carefully planned to avoid contamination of uninvolved compartments and to minimize complications, according to the American College of Radiology 1, 2

Image-guided core needle biopsy is the preferred method over open or laparoscopic biopsy, as stated by the European Society for Medical Oncology 3, 4
The retroperitoneal approach is mandatory when technically feasible, as recommended by the American College of Radiology 1, 2, 3

If malignancy is confirmed, refer immediately to a specialized sarcoma center, as adherence to evidence-based guidelines at expert centers is associated with improved survival, according to the National Comprehensive Cancer Network 4, 5
Multidisciplinary tumor board review is essential to determine whether neoadjuvant therapy (chemotherapy, radiotherapy, or both) is indicated before resection, as recommended by the European Society for Medical Oncology 3, 4, 6